drug
TUB-040
Phase 2updated 6mo agoby Tubulis GmbH
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying TUB-040
- phase2FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- phase2Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
- phase2Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
- phase2Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
News(1)
- The 6 biggest crossover rounds in biopharma historyA strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.biospace · 29d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that